SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 8, 2016, Pages 1385-1393

  Balgkouranidou, Ioanna ^a,b   Chimonidou, Maria ^a   Milaki, Georgia ^c   Tsaroucha, Emily ^d   Kakolyris, Stylianos ^b   Georgoulias, Vasilis ^c   Lianidou, Evi ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Cell free DNA; circulating tumor DNA; DNA methylation; methylation specific PCR; non small cell lung cancer; prognostic significance; SOX17

Indexed keywords

CIRCULATING TUMOR DNA; DNA; TRANSCRIPTION FACTOR SOX17; UNCLASSIFIED DRUG; SOX17 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE INTERVAL; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; NON SMALL CELL LUNG CANCER; PLASMA; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SURVIVAL TIME; BLOOD; GENETICS; LUNG TUMOR;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROMOTER REGIONS, GENETIC; SOXF TRANSCRIPTION FACTORS;

EID: 84978431573     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0776     Document Type: Article

References (38)

1. Janssen-Heijnen ML, van Erning FN, De Ruysscher DK, Coebergh JW, Groen HJ. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol 2015;5:902-7.
2. Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol 2014;32:973-82.
3. Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, et al. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions. The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2014;9:1618-24.
4. Carter BW, Glisson BS, Truong MT, Erasmus JJ. Small cell lung carcinoma: staging, imaging, and treatment considerations. Radiographics 2014;34:1707-21.
5. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-27.
6. Stella GM, Scabini R, Inghilleri S, Cemmi F, Corso S, Pozzi E, et al. EGFR and KRAS mutational profiling in fresh nonsmall cell lung cancer (NSCLC) cells. J Cancer Res Clin Oncol 2013;139:1327-35.
7. Balgkouranidou I, Liloglou T, Lianidou ES. Lung cancer epigenetics: emerging biomarkers. Biomark Med 2013;7:49-58.
8. Lou-Qian Z, Rong Y, Ming L, Xin Y, Feng J, Lin X. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis. PLoS One 2013;8:e54970.
9. Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 2004;10:6119-25.
10. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.
11. Chiu RW, Lo YM. Clinical applications of maternal plasma fetal DNA analysis: translating the fruits of 15 years of research. Clin Chem Lab Med 2013;51:197-204.
12. Marzese DM, Hirose H, Hoon DS. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn 2013;13:827-44.
13. Aung KL, Board RE, Ellison G, Donald E, Ward T, Clack G, et al. Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. Hugo J 2010;4:11-21.
14. Nie K, Jia Y, Zhang X. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer. Tumour Biol 2015;36:7-19.
15. Balgkouranidou I, Chimonidou M, Milaki G, Tsarouxa EG, Kakolyris S, Welch DR, et al. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Br J Cancer 2014;110:2054-62.
16. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37.
17. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Manegold C, et al. Prognostic significance of RASSF1A promoter methylation on survival in non small cell lung cancer patients treated with gemcitabine. Lung Cancer 2007;56:115-23.
18. Ponomaryova AA, Rykova EY, Cherdyntseva NV, Skvortsova TE, Dobrodeev AY, Zav'yalov AA, et al. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer 2013;81:397-403.
19. Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Msterberg A, et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 1990;346:245-50.
20. Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, et al. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 2007;27:7802-15.
21. Zhang W, Glkner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 2008;68:2764-72.
22. Fu DY, Wang ZM, Li-Chen, Wang BL, Shen ZZ, Huang W, et al. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat 2010;119:601-12.
23. Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 2011;57:1169-77.
24. Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou ES. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem 2013;59:270-9.
25. Kroupis C, Christopoulos K, Devetzoglou M, Tsiagas I, Lianidou ES. Asymmetric real-time PCR detection of BRCA1 mutation by melting curve analysis in the LightCycler. Clin Chim Acta 2008;390:141-4.
26. Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, et al. A rapid and accurate closedtube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples. Clin Chim Acta 2015;444:303-9.
27. Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci 2014;51:160-71.
28. Faugeroux V, Pailler E, Auger N, Taylor M, Farace F. Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer. Front Oncol 2014;4:281.
29. Marzese DM, Hoon DS. Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn 2015;15:647-64.
30. Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, et al. Cell Free DNA Working Group. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst 2014;106:dju214.
31. Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat 2014;146:163-74.
32. Ilie M, Hofman V, Long E, Bordone O, Selva E, Washetine K, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine Ann Transl Med 2014;2:107.
33. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.
34. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, et al. First-line gefitinib in Caucasian EGFR mutationpositive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014;110:55-62.
35. Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentes AA, et al. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clin Chem Lab Med 2013;51:1505-10.
36. Du YC, Oshima H, Oguma K, Kitamura T, Itadani H, Fujimura T, et al. Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology 2009;137:1346-57.
37. Li Z, Guo X, Wu Y, Li S, Yan J, Peng L, et al. Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients. Breast Cancer Res Treat 2015;149:767-79.
38. Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 2014;106:djt356.